Conditions: Relapsing Remitting Multiple Sclerosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1155
Healthy volunteers: no

Brief summary:
Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of R-R MS. GA is an immunomodulating drug that has anti inflammatory and neuroprotective properties. The study treatment duration is 12 months.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Glatiramer Acetate (GA) 40 mg intervention 2: glatiramer acetate 20 mg
Intervention descriptions: intervention 1: Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months intervention 2: Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months

Protocol document: